188 related articles for article (PubMed ID: 8013758)
1. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production.
Perriello G; Misericordia P; Volpi E; Santucci A; Santucci C; Ferrannini E; Ventura MM; Santeusanio F; Brunetti P; Bolli GB
Diabetes; 1994 Jul; 43(7):920-8. PubMed ID: 8013758
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
Cusi K; Consoli A; DeFronzo RA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4059-67. PubMed ID: 8923861
[TBL] [Abstract][Full Text] [Related]
3. Contribution of obesity to defects of intracellular glucose metabolism in NIDDM.
Chung JW; Suh KI; Joyce M; Ditzler T; Henry RR
Diabetes Care; 1995 May; 18(5):666-73. PubMed ID: 8586004
[TBL] [Abstract][Full Text] [Related]
4. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects.
Halberstam M; Cohen N; Shlimovich P; Rossetti L; Shamoon H
Diabetes; 1996 May; 45(5):659-66. PubMed ID: 8621019
[TBL] [Abstract][Full Text] [Related]
5. Contribution of obesity to insulin resistance in noninsulin-dependent diabetes mellitus.
Perriello G; Misericordia P; Volpi E; Pampanelli S; Santeusanio F; Brunetti P; Bolli GB
J Clin Endocrinol Metab; 1995 Aug; 80(8):2464-9. PubMed ID: 7629243
[TBL] [Abstract][Full Text] [Related]
6. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus.
Groop LC; Saloranta C; Shank M; Bonadonna RC; Ferrannini E; DeFronzo RA
J Clin Endocrinol Metab; 1991 Jan; 72(1):96-107. PubMed ID: 1986032
[TBL] [Abstract][Full Text] [Related]
7. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM.
Widén EI; Eriksson JG; Groop LC
Diabetes; 1992 Mar; 41(3):354-8. PubMed ID: 1551495
[TBL] [Abstract][Full Text] [Related]
8. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue.
Abbasi F; Kamath V; Rizvi AA; Carantoni M; Chen YD; Reaven GM
Diabetes Care; 1997 Dec; 20(12):1863-9. PubMed ID: 9405908
[TBL] [Abstract][Full Text] [Related]
9. Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance.
Del Prato S; Matsuda M; Simonson DC; Groop LC; Sheehan P; Leonetti F; Bonadonna RC; DeFronzo RA
Diabetologia; 1997 Jun; 40(6):687-97. PubMed ID: 9222649
[TBL] [Abstract][Full Text] [Related]
10. Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes.
Torlone E; Britta M; Rambotti AM; Perriello G; Santeusanio F; Brunetti P; Bolli GB
Diabetes Care; 1993 Oct; 16(10):1347-55. PubMed ID: 8269792
[TBL] [Abstract][Full Text] [Related]
11. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.
Groop LC; Bonadonna RC; DelPrato S; Ratheiser K; Zyck K; Ferrannini E; DeFronzo RA
J Clin Invest; 1989 Jul; 84(1):205-13. PubMed ID: 2661589
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
13. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus.
Vaag A; Henriksen JE; Madsbad S; Holm N; Beck-Nielsen H
J Clin Invest; 1995 Feb; 95(2):690-8. PubMed ID: 7860750
[TBL] [Abstract][Full Text] [Related]
14. Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin.
Damsbo P; Hermann LS; Vaag A; Hother-Nielsen O; Beck-Nielsen H
Diabetes Care; 1998 Sep; 21(9):1489-94. PubMed ID: 9727896
[TBL] [Abstract][Full Text] [Related]
15. Metabolic effects of hyperglycemia and hyperinsulinemia on fate of intracellular glucose in NIDDM.
Henry RR; Gumbiner B; Flynn T; Thorburn AW
Diabetes; 1990 Feb; 39(2):149-56. PubMed ID: 2227122
[TBL] [Abstract][Full Text] [Related]
16. Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDM.
Vaag A; Alford F; Henriksen FL; Christopher M; Beck-Nielsen H
Diabetologia; 1995 Mar; 38(3):326-36. PubMed ID: 7758880
[TBL] [Abstract][Full Text] [Related]
17. Effect of obesity on insulin resistance in normal subjects and patients with NIDDM.
Ludvik B; Nolan JJ; Baloga J; Sacks D; Olefsky J
Diabetes; 1995 Sep; 44(9):1121-5. PubMed ID: 7657038
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus.
Del Prato S; Bonadonna RC; Bonora E; Gulli G; Solini A; Shank M; DeFronzo RA
J Clin Invest; 1993 Feb; 91(2):484-94. PubMed ID: 8432857
[TBL] [Abstract][Full Text] [Related]
19. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents.
Gulli G; Ferrannini E; Stern M; Haffner S; DeFronzo RA
Diabetes; 1992 Dec; 41(12):1575-86. PubMed ID: 1446799
[TBL] [Abstract][Full Text] [Related]
20. Assessment of hepatic insulin action in obese type 2 diabetic patients.
Staehr P; Hother-Nielsen O; Levin K; Holst JJ; Beck-Nielsen H
Diabetes; 2001 Jun; 50(6):1363-70. PubMed ID: 11375337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
